NCT05952453View on ClinicalTrials.gov

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/taxol/pembro, Maintenance Olaparib/pembro

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

October 30, 2028

Study Completion Date

December 30, 2030

Conditions

Ovarian Cancer

Interventions

DRUG

Carboplatin

neoadjuvant treatment , followed by surgery, then maintenance chemotherapy

DRUG

olaparibp, embro

maintenance chemotherapy : olaparib, pembro

Trial Locations (1)

35294

RECRUITING

O'Neal Comprehensive Cancer Center at UAB, Birmingham

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Alabama at Birmingham

OTHER

NCT05952453 - Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/taxol/pembro, Maintenance Olaparib/pembro | Biotech Hunter | Biotech Hunter